Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy


Aguiar C., Alegria E., Bonnadonna R. C. , Catapano A. L. , Consentido F., Elisaf M., ...More

CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, vol.28, no.2, pp.87-93, 2016 (Journal Indexed in ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 2
  • Publication Date: 2016
  • Doi Number: 10.1016/j.arteri.2015.12.001
  • Title of Journal : CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS
  • Page Numbers: pp.87-93

Abstract

LDLc levels are associated with increase of cardiovascular risk, and statins are currently used for their control. Nevertheless, a despite of LDLc levels at goal, a residual risk is persistent, commonly associated with persistent lipids modifications (high triglycerides and low HDLc). So, it is necessary to evaluate triglycerides and HDL to assessment cardiovascular risk.